News

Based on positive results demonstrated in previous studies of Pyratine-6 (0.1%), for the remediation of photodamaged skin and erythema which included unprecedented reduction in facial redness, in as

GeneCards will be utilized to assist the Japan Patent Office (JPO) in the review and approval of patent applications in the life sciences area. With this agreement, GeneCards

Minerva used its proprietary nanoparticle technology to elucidate a key molecular mechanism that is involved in cancer cell growth and metastasis. The study focused on a cell surface

The Gore Reduce clinical study is a prospective, randomized, multi-center, multinational trial designed to demonstrate safety and effectiveness of the Gore Helex Septal Occluder for patent foramen ovale

The revised warning will now read as follows: “The breast cavity must be imaged before implantation to ensure the applicator will fit appropriately. Do not use if the

According to Rick Pauls, DiaMedica’s interim president and CEO, the 20 patient single-blind trial will demonstrate DM-83’s level of effectiveness in controlling blood glucose and insulin levels in

The trial successfully met its objectives of evaluating the safety profile and pharmacokinetic of CF102 single doses, and of determining a dose range for future clinical studies. CF102

ParagonDx’s genotyping assay is said to be the first cleared product to deliver results in less than one hour and incorporate human genomic quality controls. The ParagonDx test

Tecnica Scientifica Service Medical (TSS Medical) has purchased this additional inventory to meet demand in Italy and other EU counties. Andrew Whelan, president and CEO of BioElectronics, said: